Novo-Backed Drugmaker Avalyn Raises $300 Million in Upsized IPO

Avalyn Pharma Inc., a biopharma company developing inhaled treatments for rare lung diseases, raised $300 million in a US initial public offering that priced at the top of its marketed range.

Comments

comments